2022
DOI: 10.1007/s00415-022-11213-9
|View full text |Cite
|
Sign up to set email alerts
|

Isolated REM sleep behaviour disorder: current diagnostic procedures and emerging new technologies

Abstract: Isolated REM sleep behaviour disorder (iRBD) is characterised by dream enactment behaviours, such as kicking and punching while asleep, and vivid/violent dreams. It is now acknowledged as a prodromal phase of neurodegenerative disease—approximately 80% of people with iRBD will develop dementia with Lewy Bodies, Parkinson’s disease or another degenerative brain disease within 10 years. It is important that neurologists and other clinicians understand how to make an early accurate diagnosis of iRBD so that affec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 61 publications
(91 reference statements)
0
6
0
Order By: Relevance
“…The RBDSQ has been found to have high diagnostic accuracy in healthy controls, with 96% sensitivity and 96% specificity. However, when including patients with other sleep disorders, the specificity drops to only 56% 19 . Validation of current scales are necessary to ensure reproducibility, reliability, and accuracy as polysomnography‐defined RBD data become available.…”
Section: Discussionmentioning
confidence: 99%
“…The RBDSQ has been found to have high diagnostic accuracy in healthy controls, with 96% sensitivity and 96% specificity. However, when including patients with other sleep disorders, the specificity drops to only 56% 19 . Validation of current scales are necessary to ensure reproducibility, reliability, and accuracy as polysomnography‐defined RBD data become available.…”
Section: Discussionmentioning
confidence: 99%
“…A biomarker is a measurable characteristic indicating normal or pathogenic biological processes or pharmacological responses to therapeutic drugs (Miglis et al, 2021). Biomarkers used for diagnosis of and fMRI), and genetic biomarker (GBA variants, SNCA, TMEM175) (Bramich et al, 2022;Gnarra et al, 2023;Zhang et al, 2023).…”
Section: Introductionmentioning
confidence: 99%
“…A biomarker is a measurable characteristic indicating normal or pathogenic biological processes or pharmacological responses to therapeutic drugs (Miglis et al., 2021 ). Biomarkers used for diagnosis of iRBD patients include neurophysiological (polysomnography, actigraphy, electroencephalogram), clinical (hyposmia, cognitive dysfunction, visual dysfunction, motor function, autonomic function) and biological biomarker (blood test, CSF, tissue biopsy), neuroimaging (positron emission tomography [PET], single‐photon emission computed tomography [SPECT], structural magnetic resonance imaging [MRI], DWI and fMRI), and genetic biomarker (GBA variants, SNCA, TMEM175) (Bramich et al., 2022 ; Gnarra et al., 2023 ; Zhang et al., 2023 ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Screening questionnaires for iRBD can be useful but they tend to overestimate the prevalence, as some symptoms of iRBD may be present in other conditions, such as obstructive sleep apnea, periodic limb movement disorder, or nightmare disorder. The features of limb movements and frequent awakenings seen in these other conditions show how initial suspicion of iRBD can be missed with screening questionnaires alone (Bramich et al, 2022). Additionally, the low specificity and positive predictive value of iRBD screening questionnaires, along with the need to develop other methods for appropriate screening of iRBD, have recently been highlighted (Stefani et al, 2023).…”
mentioning
confidence: 99%